Article metrics

Download PDFPDF

588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)

 

Online download statistics by month:

Online download statistics by month: November 2023 to March 2024

AbstractFullPdf
Nov 2023216014
Dec 20236907
Jan 20246006
Feb 20244407
Mar 20243803
Total427037